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Abstract
Human papillomaviruses (HPV) activate a number of host factors to control their differentia-
tion-dependent life cycles. The transcription factor signal transducer and activator of tran-
scription (STAT)-3 is important for cell cycle progression and cell survival in response to
cytokines and growth factors. STAT3 requires phosphorylation on Ser727, in addition to
phosphorylation on Tyr705 to be transcriptionally active. In this study, we show that STAT3
is essential for the HPV life cycle in undifferentiated and differentiated keratinocytes. Pri-
mary human keratinocytes containing high-risk HPV18 genomes display enhanced STAT3
phosphorylation compared to normal keratinocytes. Expression of the E6 oncoprotein is suf-
ficient to induce the dual phosphorylation of STAT3 at Ser727 and Tyr705 by a mechanism
requiring Janus kinases and members of the MAPK family. E6-mediated activation of
STAT3 induces the transcription of STAT3 responsive genes including cyclin D1 and Bcl-
xL. Silencing of STAT3 protein expression by siRNA or inhibition of STAT3 activation by
small molecule inhibitors, or by expression of dominant negative STAT3 phosphorylation
site mutants, results in blockade of cell cycle progression. Loss of active STAT3 impairs
HPV gene expression and prevents episome maintenance in undifferentiated keratinocytes
and upon differentiation, lack of active STAT3 abolishes virus genome amplification and late
gene expression. Organotypic raft cultures of HPV18 containing keratinocytes expressing a
phosphorylation site STAT3 mutant display a profound reduction in suprabasal hyperplasia,
which correlates with a loss of cyclin B1 expression and increased differentiation. Finally,
increased STAT3 expression and phosphorylation is observed in HPV positive cervical
disease biopsies compared to control samples, highlighting a role for STAT3 activation in
cervical carcinogenesis. In summary, our data provides evidence of a critical role for STAT3
in the HPV18 life cycle.
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Author summary
Human papillomaviruses (HPV) are the leading cause of viral induced cancers worldwide.
HPV are the causative agents of cervical cancers and an increasing number of head and
neck cancers. HPV infections are dependant on the manipulation of the host cell for their
replication and this may result in diseases such as cancer. The STAT3 transcription factor,
a known driver of cancer progression, is often over active in HPV-associated cancers;
however, its role in the life cycle of HPV has not been studied. Using primary cell culture
models we provide the first evidence demonstrating that HPV increases both the phos-
phorylation and activity of STAT3 and that this is required for viral gene expression and
replication. Importantly, inhibition of STAT3 by small molecule inhibitors or expression
of STAT3 mutants that cannot be phosphorylated impairs the HPV life cycle. Finally, we
demonstrate that STAT3 phosphorylation is increased during cervical disease progression,
highlighting the potential of STAT3 as a novel therapeutic target in HPV-associated
cancers.
Introduction
Human papillomaviruses (HPVs) are small, non-enveloped double-stranded DNA viruses that
show a tropism for squamous epithelial cells of the skin epidermis, oral and ano-genital mucosa.
Infection with HPV is associated with a spectrum of clinical manifestations ranging from com-
mon warts to cancers [1]. Whilst>200 types of HPV have been identified (https://pave.niaid.
nih.gov/), only a sub-set of these are classed as high-risk due to their association with malig-
nancy. High-risk HPVs are responsible for>99% of cervical cancer cases and a growing num-
ber of oropharyngeal carcinomas [2,3]. In particular, high-risk HPV16 and HPV18 are detected
in>70% of cervical cancer cases and over 90% of other HPV positive cancers [4].
The HPV life cycle is intrinsically linked to the terminal differentiation programme of the
epithelial tissues they infect, with productive replication restricted to differentiated suprabasal
cells. Following infection of mitotically active cells within the basal layer of the epithelium,
HPV genomes are established as low copy (~100 copies) number episomes [5]. Upon differen-
tiation, HPV infected cells remain active in the cell cycle and re-enter S/G2 phases for virus
genome amplification. In the upper layers of the epithelium, infected cells exit the cell cycle
and complete differentiation, enabling transit to the late stage of infection, where the late pro-
moter is activated to drive late gene expression prior to virion production [5]. HPV replication
is dependent on host factors, which are mainly controlled by the activities of the virus encoded
E5, E6 and E7 proteins. Whilst the role of the E5 protein is less understood [6], the E6 and E7
oncoproteins are pivotal in the productive life cycle as well as in the development of anogenital
cancers [7]. E7 proteins promote S phase re-entry in the differentiated strata via an ability to
bind and inactivate the pocket family proteins pRb, p107 and p130. These interactions result
in release of the transcription factor E2F, causing cell cycle progression in cells that would nor-
mally be undergoing differentiation [8,9]. E6 recruits the cellular ubiquitin ligase E6-associated
protein (E6AP) into a protein complex with the tumour suppressor protein p53, resulting in
its degradation [10,11]. In addition, high-risk E6 proteins bind and degrade a select group of
PSD95/DLG/ZO-1 (PDZ) domain containing proteins [12]. Disruption of either of these func-
tions interferes with the HPV life cycle [13–16]. Despite our increased understanding of the
HPV life cycle, there is still a clear need to understand how HPV and the host cell proteins it
manipulates determine the outcome of HPV infection to define novel strategies to treat HPV
infections.
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STAT3 is a member of the signal transducer and activator (STAT) family of transcription
factors that were originally discovered through their capacity to mediate transcription in
response to interferons [17]. Binding of cytokines and growth factors to cell surface receptors
results in activation of STAT3, which typically involves phosphorylation of a tyrosine (Y705)
residue [18]. Phosphorylation is primarily mediated by receptor-associated kinases (e.g. Janus
family kinases (JAK)) and receptor tyrosine kinases (e.g. epidermal growth factor receptor
(EGFR)), but can also be accomplished by non-receptor tyrosine kinases such as Src [19,20].
Tyrosine phosphorylated STAT3 molecules form activated dimers and translocate to the
nucleus where they initiate a programme of gene expression controlling fundamental biologi-
cal processes such as proliferation, apoptosis, immune regulation and differentiation [21].
STAT3 is also subject to stimulus-dependent phosphorylation of a serine (S727) residue in its
transactivation domain [18]. The function of this additional phosphorylation event remains
controversial, as the modification has been reported to enhance and suppress STAT3 tran-
scriptional activity [22,23].
In stratified epithelia, STAT3 drives proliferation and is required to maintain cells in an
undifferentiated state by actively impairing differentiation [24–26]. Genetically engineered
STAT3 knockout mice show reduced epithelial proliferation and suffer a compromised wound
healing response [27]. In addition, both maintenance and renewal of keratinocyte stem cells is
impaired. In contrast, mice engineered to express a constitutively active STAT3 in the prolifer-
ative compartment of the epithelium exhibit a disturbed gene expression profile resulting in
an enrichment of expression of genes associated with epithelial to mesenchymal transition
[28]. Keratinocytes from these mice display an increased survival rate in response to chemical
insult or exposure to UV radiation [29]. Constitutive activation of STAT3 is also a feature of
many human malignancies including cervical, and head and neck cancers, and is associated
with a poor prognosis in various tumours [30]. Such aberrant activation of STAT3 contributes
to tumour initiation, progression, immune evasion and metastasis [21,31]. Despite a clear link
between STAT3 activation and HPV-associated cancers, it is not known whether STAT3 con-
tributes to the productive HPV life cycle. This is surprising given the important role of STAT3
in maintaining an undifferentiated phenotype in keratinocytes.
Here, we show that STAT3 phosphorylation is increased in HPV18-positive cells, and
maintained during differentiation, through the activities of JAK and MAPK family kinases.
Increased STAT3 activity is associated with host gene expression changes, including over-
expression of proteins required for cell cycle progression and cell survival. Importantly, block-
ade of STAT3 activity through small molecule inhibitors, siRNA mediated depletion or over-
expression of dominant negative phosphorylation null STAT3 mutants impairs viral gene
expression and viral DNA replication in undifferentiated and differentiated cells. Finally, we
demonstrate that phosphorylation is essential for STAT3 function in the HPV replication cycle
and is frequently increased in HPV-positive cervical disease. Thus, STAT3 is a critical host fac-
tor required during the high-risk HPV life cycle.
Results
HPV18 enhances STAT3 phosphorylation in primary human keratinocytes
To investigate the role of STAT3 in the HPV18 life cycle, stable cell lines harbouring HPV18
episomes were generated from two primary foreskin keratinocyte donors. To exclude donor
effects, all experiments were performed using both donor lines and representative data are pre-
sented. Levels of STAT3 phosphorylation were measured in normal human keratinocytes
(NHK) and HPV18-containing cells by western blotting. In undifferentiated cells, phosphory-
lation of the major tyrosine (Y705) and serine (S727) residues was enhanced significantly in
HPV activates STAT3
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006975 April 9, 2018 3 / 33
keratinocytes harbouring HPV18 compared to NHK donor controls (Fig 1A, compare lanes 1
and 4, Fig 1B, showing combined data from two donors; N = 8 p<0.05). To ascertain whether
STAT3 phosphorylation was further modulated during keratinocyte differentiation, mono-
layer cultures of NHK and HPV18-containing cells were cultured in high calcium media for 72
hours and samples taken for western blot analysis. Keratinocyte differentiation was confirmed
by increased involucrin expression (Fig 1A). Importantly, whilst subject to a decline, enhanced
STAT3 phosphorylation was maintained at detectable levels in the HPV18-containing cells
Fig 1. HPV18 induces the activation of STAT3 in primary human keratinocytes. A) Representative western blots of normal human keratinocytes (NHK)
and HPV18-containing keratinocytes subjected to high calcium differentiation and analysed for STAT3 phosphorylation using specific antibodies against
pS727 STAT3, pY705 STAT3 and total STAT3. Involucrin expression is a marker of differentiation and E7 demonstrates the presence of HPV18 in the
samples. GAPDH serves as a loading control. B) Quantification of the protein band intensities in A) standardised to GAPDH levels. Bars represent the
means ± standard deviation from 4 independent biological repeats using 2 donor cell lines. P<0.05 (Student’s t-test). Representative sections of organotypic
raft cultures from C) NHK and D) HPV18-containing keratinocytes stained with antibodies specific for pS727 STAT3 and total STAT3 (green) and
counterstained with DAPI to highlight the nuclei (blue in the merged panels). Images were acquired using identical exposure times. Scale bar, 40 μm. White
dotted lines indicate the basal cell layer.
https://doi.org/10.1371/journal.ppat.1006975.g001
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during differentiation (Fig 1A, compare lanes 2 and 5, 3 and 6). In contrast, HPV18 had no
effect upon the total levels of STAT3 protein in the primary keratinocytes (Fig 1A). Compara-
ble STAT3 phosphorylation changes were observed in both donor samples.
Next, we confirmed our findings in an additional model of keratinocyte differentiation.
NHK and HPV18-containing cells were stratified in organotypic raft culture for 14 days; this
method recapitulates all stages of the HPV life cycle [32]. Raft sections were stained with
antibodies detecting the total and phosphorylated forms of STAT3 (representative sections
from one donor shown in Fig 1C and 1D). Staining of total STAT3 protein was comparable
between the donor-matched NHK and HPV18-containing rafts. S727 phosphorylated
STAT3 was evident in both the basal and suprabasal layers of the NHK and HPV18 contain-
ing rafts. However, the level of the S727 phosphorylated form of STAT3 was elevated in the
presence of HPV18 (Fig 1C and 1D). We were not able to successfully stain raft cultures with
the Y705 STAT3 phosphorylation specific antibody and so could not confirm the results
obtained from our calcium differentiation assays. However, our data clearly demonstrate
that primary keratinocytes harbouring HPV18 genomes exhibit increased STAT3
phosphorylation.
HPV18 E6 is necessary and sufficient for the dual phosphorylation and
activation of STAT3
Next, we hypothesised that a virus-encoded oncoprotein (E5, E6 and E7) promotes the
increased STAT3 phosphorylation observed in the HPV18 life cycle model. To determine
whether one or more of the HPV18 oncoproteins was responsible for STAT3 activation, the
levels of STAT3 phosphorylation were measured by western blot analysis of C33a (an HPV-
negative cervical carcinoma cell line) cells expressing individual GFP-tagged HPV18 oncopro-
teins (Fig 2A). Interestingly, all three oncoproteins increased Y705 STAT3 phosphorylation
compared to cells expressing GFP alone (compare lanes 1 with 2, 3 and 4); E5 by average of 3
fold (p<0.05), E6 by an average of 4.1 fold (p<0.05) and E7 by an average of 3.6 fold (p<0.05)
(Fig 2A, lanes 2–4). Overexpression of both E5 and E7 led to a small increase in S727 STAT3
phosphorylation, however, E6 expression increased S727 phosphorylation significantly by an
average of 5.6 fold (p<0.01) (Fig 2A, lane 3). In agreement with our observations from primary
keratinocytes, the presence of the HPV oncoproteins did not alter the level of total STAT3 pro-
tein, which remained similar to the GFP control.
Next, we investigated whether the viral oncoproteins are responsible for the increased
STAT3 phosphorylation observed in primary keratinocytes harbouring the HPV18 genomes.
For this, we silenced E6 expression in the HPV18 life cycle model using a pool of E6-specific
siRNA and compared the levels of phosphorylated STAT3 to those of cells transfected with a
scrambled control siRNA (S1A Fig). Treatment with the E6-siRNA resulted in a loss of E6
expression coupled to an increase in levels of the E6 target p53 (S1A Fig). Importantly, the loss
of E6 also correlated with a significant reduction in both Y705 and S727 STAT3 phosphoryla-
tion (p<0.001). Our E6 depletion approach also resulted in decreased E7 expression (average
of 55%) (S1A Fig). To rule out any contributory role for this oncoprotein, we tested whether
targeted siRNA-mediated depletion of E7 also affected STAT3 phosphorylation. Treatment of
HPV18 genome-containing cells with E7-specific siRNA reduced E7 expression by approxi-
mately 60% without impacting on either E6 expression or STAT3 phosphorylation (S1B Fig).
To test the contribution of the E5 oncoprotein we utilised our recently generated primary ker-
atinocyte lines containing an E5 knockout HPV18 genome [33]. Using this system we showed
that loss of E5 did not reduce STAT3 phosphorylation in either monolayer cultures differenti-
ated in high calcium media or organotypic raft cultures (S1C and S1D Fig). In summary, these
HPV activates STAT3
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Fig 2. HPV E6 promotes the dual phosphorylation and activation of STAT3. A) Representative western blot of
C33a cells transfected with GFP tagged HPV18 oncoproteins E5, E6 or E7 and analysed for STAT3 activation using
specific antibodies detecting phosphorylated and total STAT3. Expression of HPV oncoproteins was confirmed using a
GFP antibody. GAPDH served as a loading control. B) Representative luciferase reporter assays from C33a cells co-
transfected with GFP tagged HPV18 oncoproteins E5, E6 or E7 and either a β-casein promoter reporter plasmid or a
HPV activates STAT3
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data indicate that E6 is the predominant protein responsible for increasing the STAT3 phos-
phorylation observed in HPV18-containing keratinocytes.
To address whether increased STAT3 phosphorylation correlated with enhanced STAT3
transactivation, we measured the promoter activity of two STAT3-dependent reporter plas-
mids. C33a cells were co-transfected with isolated HPV oncoproteins and reporter plasmids
driving firefly luciferase from the β-casein [34] and pro-opiomelanocortin (PomC) [35] pro-
moters. Expression of HPV18 E5 and E7 did not significantly increase STAT3-dependent
luciferase expression. Conversely, expression of HPV18 E6 led to an average 8-fold increase in
β-casein promoter-driven luciferase (p<0.01) and a 5.5-fold increase in PomC-driven lucifer-
ase (p<0.01) (Fig 2B). Whilst these reporter constructs have been widely used to monitor the
activation of STAT3, they can also be responsive to other members of the STAT family of tran-
scription factors [35,36]. In this regard, a recent study has shown that HPV activates STAT5,
which is necessary for HPV31 genome amplification [37]. To exclude the possibility that the
observed increase in luciferase expression was a result of STAT5 activation, we used a pharma-
cological approach to specifically block the activation of STAT3 and STAT5 (Fig 2C). Trans-
fected C33a cells were treated with the STAT5 inhibitor pimozide [37] or two chemically
distinct STAT3 inhibitors, cryptotanshinone and S3I-201. Firstly, we confirmed that crypto-
tanshinone (S2A Fig) treatment did not affect STAT5 phosphorylation in HPV18-containing
keratinocytes. Importantly, cells treated with pimozide showed no reduction in luciferase
expression whereas in contrast, treatment with the two STAT3 inhibitors resulted in a signifi-
cant (p<0.01) reduction in β-casein-driven luciferase expression (Fig 2C).
We next assessed if E6 could induce the expression of endogenous STAT3-dependent gene
products. Expression of HPV18 E6 in C33a cells led to increased expression of cyclin D1 and
Bcl-XL, two characterised STAT3-dependent gene products (Fig 2D). To confirm that the
induction of cyclin D1 and Bcl-xL was STAT3-dependent, E6 expressing cells were treated
with cryptotanshinone and S3I-201. Treatment with either inhibitor reduced STAT3 phos-
phorylation at both tyrosine and serine residues, but had minimal impact on levels of total
STAT3 protein. In addition, inhibitor treatment reduced cyclin D1 and Bcl-xL expression to
control levels (Fig 2D). Quantitative reverse transcriptase-PCR (qRT-PCR) revealed E6-depen-
dent increases in cyclin D1(ccnd1) and Bcl-XL (bcl2l1) mRNA transcripts, and these increases
were sensitive to treatment with STAT3 inhibitors (ccnd1 plus crypto p<0.01 and bcl2l1 plus
crypto p<0.05) (Fig 2E and 2F). Additional STAT3-dependent genes, including HIF1α and
Survivin (birc5), were up-regulated by E6 in a STAT3-dependent manner (hif1α plus crypto
p<0.05 and birc5 plus crypto p<0.001) (Fig 2G and 2H). Based on these results, we conclude
that the E6 oncoprotein increases the transcription of STAT3-dependent genes.
PomC reporter plasmid, which contain STAT3 binding sites, and promoter activity measured using a dual-luciferase
system. Data are presented as relative to the GFP transfected control cells. Bars represent the means ± standard
deviation from at least three independent biological repeats. P<0.01, N.S. = not significant (Student’s t-test). C)
Representative luciferase reporter assays from C33a cells co-transfected with GFP tagged E6 and a β-casein promoter
reporter plasmid treated with the STAT3 inhibitors cryptotanshinone and S3I-201, and the STAT5 inhibitor pimozide.
Promoter activity was measured using a dual-luciferase system. Data are presented as relative to the GFP transfected
control. Bars represent the means ± standard deviation from at least three independent biological repeats. P<0.01
(Student’s t-test). D) Representative western blot of C33a cells transfected with GFP or GFP tagged HPV18 E6,
untreated or treated with the STAT3 inhibitors as above and analysed for total and phosphorylated STAT3 (Y705 and
S727), the expression of cyclin D1 and Bcl-xL and GFP to demonstrate expression of the GFP-18E6 fusion protein.
GAPDH expression was used as a loading control. Data shown are representative of at least three biological repeats.
E-H) C33a cells were transiently transfected with GFP or GFP tagged HPV18 E6 and left untreated or treated with the
STAT3 inhibitors as above and RNA was extracted for qRT-PCR analysis of the indicated STAT3 dependent genes.
Samples were normalized against U6 mRNA levels. Representative data are presented relative to the GFP transfected
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STAT3 is phosphorylated in cells expressing E6 mutants defective for E6AP
binding, p53 degradation and PDZ domain-binding
Whilst E6 proteins lack intrinsic enzymatic activities, those E6 proteins encoded by high-risk
HPVs are able to interact with key cellular partners including E6AP, p53 and a number of
PDZ-domain containing proteins to modulate cellular functions [38–40]. Therefore, we tested
whether these interactions were required for the E6-mediated increase in STAT3 phosphoryla-
tion observed in HPV-positive cells. To this end, STAT3 phosphorylation was measured in
cells expressing wild type and mutant HPV18 E6 proteins deficient in their ability to bind p53,
E6AP or PDZ domains. Valine substitution of phenylalanine at amino acid position four
(F4V) generates an E6 protein incapable of destabilizing p53 and in a HPV18 life cycle model
is deficient in supporting viral DNA amplification [41]. Whilst deficient for inhibiting p53
destabilization, the E6 F4V mutant enhanced STAT3 phosphorylation to levels comparable
with wild type E6 (Fig 3A; compare lanes 2 and 4). E6 expression leads to the degradation of
p53 by virtue of its interaction with the E6AP E3 ubiquitin ligase. Expression of an E6 mutant
unable to interact with E6AP (L52A) [42] impaired p53 degradation, but retained the ability to
enhance STAT3 phosphorylation (Fig 3A; compare lanes 2 and 5). To test whether E6 interac-
tion with PDZ proteins was required for increased STAT3 phosphorylation, we engineered
HPV18 E6 ΔPDZ, which lacks the C-terminal four amino acid PDZ-binding motif and cannot
bind to PDZ domains [13]. When expressed in C33a cells, this mutant protein induced STAT3
phosphorylation to wild type E6 levels (Fig 3A; compare lanes 2 and 3). Finally, we confirmed
that the PDZ-binding domain of E6 was not required for STAT3 phosphorylation in the con-
text of the entire HPV genome in a differentiating epithelium. Organotypic raft cultures were
generated from NHK harbouring wild type and ΔPDZ HPV18 genomes [13]. Rafts were
stained with an antibody that detects the pS727 form of STAT3. A similar pattern of STAT3
S727 phosphorylation was observed throughout the basal and suprabasal layers of the HPV18
wild type and ΔPDZ containing rafts (Fig 3B). Together these data demonstrate that STAT3
phosphorylation is increased in cells expressing HPV18 by a mechanism independent of the
p53 destabilizing and PDZ binding functions of E6.
Janus kinases (JAK) are responsible for STAT3 Y705 phosphorylation in
HPV18 containing keratinocytes
Janus family receptor-associated tyrosine kinases are the most common kinases responsible
for mediating STAT3 Y705 phosphorylation, which is deemed necessary for STAT3 activation
[30]. Previous studies have shown that treatment of SiHa HPV16-positive cervical cancer cells
with AG490, a non-specific JAK2 inhibitor, prevented STAT3 Y705 phosphorylation [43],
however, such studies have not been performed in primary keratinocytes. To address this, we
first confirmed that JAK were active in primary keratinocytes harbouring HPV18 by western
blot analysis for tyrosine phosphorylated JAK2. Levels of phosphorylated JAK2 were higher in
HPV18-containing keratinocytes compared to NHK controls, and were retained during cal-
cium-mediated differentiation (Fig 4A). Next, we showed that increased JAK phosphorylation
was E6-dependent by overexpressing a GFP HPV18 E6 fusion protein in C33a cells. Western
blot analysis showed an increase in JAK phosphorylation in C33a cells expressing GFP-18E6
compared to GFP control (Fig 4B; compare lanes 1 and 2). Lastly, we incubated HPV18-con-
taining keratinocytes with the highly specific clinically available JAK1/2 inhibitor Ruxolitinib
[44], or the JAK2 inhibitor Fedratinib [45]. Treatment with either inhibitor led to a marked
reduction in STAT3 Y705 phosphorylation without affecting S727 phosphorylation (Fig 4C;
compare lane 1 to 2 and 3). These results indicate that JAK2 mediates the STAT3 Y705 phos-
phorylation in HPV18-containing primary keratinocytes.
HPV activates STAT3
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Functionally redundant MAPK proteins mediate STAT3 S727
phosphorylation in HPV18-containing keratinocytes
A number of candidate STAT3 S727 kinases have emerged including; CDK5 [46], mTOR [47],
NEMO-like kinase (NLK) [48] and several PKC isoforms [49,50]. However, the strongest evi-
dence indicates that MAPK members mediate the serine phosphorylation of STAT3 [18]. The
plethora of kinases capable of phosphorylating STAT3 implies that under physiological condi-
tions this event might be restricted by cell type or the nature of the stimulus. We therefore set
out to determine which kinases were responsible for STAT3 S727 phosphorylation in keratino-
cytes harbouring HPV18 genomes. We focused on the canonical MAPK members since S727
is embedded within a strong MAPK consensus sequence (725PMSP728). To determine whether
MAPK members could directly phosphorylate STAT3, purified recombinant JNK1, ERK2 and
p38α were subject to an in vitro kinase assay by using bacterially expressed and purified
STAT3 as the substrate. All three kinases successfully phosphorylated STAT3 (S3 Fig). Whilst
data generated from in vitro kinase assays demonstrates the ability of a kinase to directly phos-
phorylate a substrate, it is essential to confirm that the kinase in question is active in cell cul-
ture. To this end, we tested the activation status of each of the canonical MAPK members in
differentiating keratinocytes. In these studies, levels of total ERK1/2 were increased in
HPV18-containing keratinocytes compared to NHK controls (Fig 5A; compare lanes 1–3 and
4–6). In accordance with a key role in keratinocyte proliferation, keratinocytes displayed
detectable ERK1/2 phosphorylation [51] (Fig 5A). As expected, both basal and differentiation-
induced ERK1/2 phosphorylation was greater in HPV positive cells (compare lanes 1 and 4,
and lanes 3 and 6). Whereas total p38 protein expression did not alter in the presence of
HPV18, the levels of p38 phosphorylation were greater in both undifferentiated and differenti-
ated HPV18-containing keratinocytes (Fig 5A; compare lanes 1 and 4, 3 and 6). In contrast
Fig 3. STAT3 is phosphorylated in cells expressing E6 defective for E6AP binding, p53 degradation and PDZ domain binding. A)
Representative western blot of C33a cells transfected with GFP or GFP tagged HPV18 E6 wild type, E6 ΔPDZ, E6 F4V or E6 L52A and analysed
using antibodies detecting total and phosphorylated STAT3 and p53. GAPDH expression was used as a loading control and GFP confirmed
expression of the E6 proteins. Data presented are representative of at least three independent experiments. B) Organotypic raft sections were
stained with an antibody specifically detecting STAT3 pS727 (green) and counterstained with DAPI to highlight the nuclei (blue—in merged
panels). Images were acquired with identical exposure times. The dotted line indicates the basal cell layer. Scale bar, 20 μm.
https://doi.org/10.1371/journal.ppat.1006975.g003
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with ERK1/2 and p38, less is known of JNK1/2 regulation by HPV18; however, studies demon-
strate that JNK1/2 signalling can prevent keratinocyte differentiation [52]. In keeping with this
role, levels of JNK1/2 phosphorylation were highest in undifferentiated NHKs, and decreased
rapidly upon differentiation in high calcium media (Fig 5A; compare lanes 1 and 3). JNK1/2
phosphorylation also declined in differentiating HPV18 positive keratinocytes but overall lev-
els were noticeably higher than in NHK (compare lanes 1 and 4, lanes 3 and 6). Together,
these data demonstrate the presence of active MAPK members in HPV18 genome-containing
cells. Moreover, in transient transfection experiments the phosphorylation of all three MAPK
members was increased in C33a cells expressing GFP-18E6 compared to a GFP control (Fig
5B).
To test the roles of endogenous MAPK in the regulation of STAT3, we compared the levels
of STAT3 S727 phosphorylation in undifferentiated HPV18-containing cells treated with the
p38 inhibitor VX-702 [53], the MKK1/2 inhibitor UO126 (prevents ERK1/2 phosphorylation
and activation) [54] and the JNK1/2 inhibitor JNK-IN-8 [55], alone or in combinations (Fig
5C and 5D). The STAT3 inhibitor cryptotanshinone served as a positive control in these exper-
iments and the Mitogen and Stress activated protein Kinase (MSK) inhibitor SB-747651 acted
as a negative control, given that in our tests MSK did not phosphorylate STAT3 in vitro (S3
Fig). As shown in Fig 5C, STAT3 S727 and Y705 phosphorylation were significantly (p<0.001)
Fig 4. Janus kinases (JAK) are responsible for mediating Y705 phosphorylation in E6 and HPV18 containing
keratinocytes. A) Representative western blot of keratinocytes subjected to high calcium differentiation analysed with
antibodies specific for the total and phosphorylated forms of JAK2 (Y1007/1008). GAPDH served as a loading control. Data
shown are representative of at least three independent biological repeats. B) Representative western blot of C33a cells
transfected with GFP and GFP tagged HPV18 E6 and analysed using specific antibodies detecting phosphorylated (Y1007/
1008) and total JAK2. Expression of E6 was confirmed using a GFP antibody. GAPDH served as a loading control. C)
Representative western blots of HPV18 containing keratinocytes incubated with the JAK1/2 inhibitor Ruxolitinib or JAK2
inhibitor Fedratinib analyzed with antibodies detecting total and phosphorylated forms of JAK2 and STAT3. GAPDH served
as a loading control. Data shown are representative of at least three independent biological repeats.
https://doi.org/10.1371/journal.ppat.1006975.g004
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Fig 5. Identifying the protein kinases responsible for the S727 phosphorylation of STAT3 in HPV18 containing keratinocytes. A) Representative
western blot of keratinocytes subjected to high calcium differentiation analysed with antibodies specific for the total and phosphorylated forms of ERK1/
2 (Thr202/Tyr204), p38 (Thr180/Tyr182) and JNK (Thr183/Tyr185). GAPDH served as a loading control. Data shown are representative of at least
three independent biological repeats. B) Representative western blot of C33a cells transfected with GFP and GFP tagged HPV18 E6 and analysed using
specific antibodies detecting phosphorylated and total forms of ERK1/2 (Thr202/Tyr204), p38 (Thr180/Tyr182) and JNK (Thr183/Tyr185). GAPDH
served as a loading control. C) Representative western blots of HPV18 containing keratinocytes incubated with specific inhibitors of STAT3 (Crypto),
MSK1 (SB-747651A; SB), p38 (VX-745; VX)), JNK (JNK-IN-8), MKK1/2 (UO126) or in combination as described in the methods and materials and
examined with antibodies specific for phosphorylated and total STAT3. The phosphorylation status of substrate proteins pMSK1 (T581), pcJun (S73),
pMAPKAPK2 (T334), and ERK1/2 (T202/Y204) demonstrated inhibitor efficacy and specificity. D) Quantification of the protein band intensities of (C)
standardised to GAPDH and shown relative to the DMSO control. Bars represent the means ± standard deviation from at least three independent
biological repeats. P<0.05, P<0.01, P<0.001 (Student’s t-test).
https://doi.org/10.1371/journal.ppat.1006975.g005
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impaired by cryptotanshinone (lane 2) but unaffected by the MSK inhibitor SB-747651 (lane
3). STAT3 Y705 phosphorylation remained intact in cells treated with the MAPK inhibitors,
indicating that tyrosine phosphorylation of STAT3 is not dependent on active MAPK in kera-
tinocytes. STAT3 S727 phosphorylation was largely unaffected in cells treated with VX-702
(p38 inhibitor) and JNK-IN-8, and was only partially suppressed by the MKK1/2 inhibitor
UO126 (lanes 5 (p<0.05) and 7 (p<0.01)). Importantly, the combination of UO126, VX-702
and JNK-IN-8, blocking all three MAPK members, was required to significantly (p<0.001)
reduce STAT3 S727 phosphorylation (lane 8) (Fig 5D). Western blot analysis of the phosphor-
ylated forms of the MAPK substrates MAPKAP-K2 (p38), MSK (ERK1/2) and c-Jun (JNK1/2)
were used to demonstrate the efficacy of inhibitor treatment. These data indicate that several
MAPK family members can phosphorylate STAT3 S727 in HPV18-positive keratinocytes.
Active STAT3 is required for viral gene expression in undifferentiated
primary keratinocytes
Given that STAT3 activation and the expression of STAT3-dependent genes were increased in
HPV18-positive cells, we assessed if STAT3 was necessary for the virus life cycle. For this,
STAT3 was depleted from primary keratinocytes harbouring HPV18 genomes using a panel of
four commercially validated siRNAs. Each siRNA produced a reproducible depletion of
STAT3 by an average of 38% compared to a scrambled control, and did not reduce levels of
the STAT5 protein (Fig 6A and S2B Fig). Despite the modest depletion of STAT3, expression
of the HPV18 E6 and E7 proteins was greatly reduced compared to the scrambled control (Fig
6A). To assess if the inhibition of HPV18 oncoprotein expression occurred at the level of tran-
scription, HPV18-positive keratinocytes were transfected with a pool of the STAT3 siRNA,
and total RNA isolated and assayed by qRT-PCR for the levels of STAT3, E6 and E7 tran-
scripts. STAT3 depletion (p<0.05) caused a significant decrease in early transcript expression
(E6 p<0.05, E7 p<0.05), indicating that STAT3 has a role in HPV gene expression in undiffer-
entiated cells (Fig 6B).
To rule out the possibility that siRNA studies perturbed a crucial STAT3 protein scaffolding
function [48], we used small molecule inhibitors to specifically block STAT3 phosphorylation
and transactivation whilst retaining levels of total STAT3 protein. For this, we monitored the
level of HPV protein expression in undifferentiated HPV containing keratinocytes treated
with increasing concentrations of the STAT3 inhibitor cryptotanshinone. As shown in Fig 6C,
inhibitor treatment reduced STAT3 phosphorylation in a dose dependent manner without
affecting total STAT3 levels. Importantly, cryptotanshinone treatment had no adverse effect
upon keratinocyte viability during the term of the experiment (S4 Fig). Concentrations of
cryptotanshinone that blocked STAT3 phosphorylation also decreased E6 and E7 protein (Fig
6C) and mRNA transcript levels (p<0.05) (Fig 6D).
Next, we wished to demonstrate the contribution of the individual Y705 and S727 phos-
phorylation events to STAT3 regulation of HPV oncogene expression. This was important
given that an emphasis has been placed on Y705 phosphorylation as a critical step in STAT3
activation; however, under certain circumstances S727 phosphorylation is necessary for full
STAT3 transactivation [18]. Dominant negative forms of STAT3 were used in which Y705
was replaced with a phenylalanine or S727 substituted with an alanine, generating mutants
with a single unphosphorylatable site [56,57]. The STAT3 mutants were expressed in HPV18-
containing keratinocytes, and over-expression of the Y705F mutant confirmed by western
blot with an anti-FLAG antibody (the pFugW-Y705F plasmid encodes a FLAG-epitope tagged
STAT3) (Fig 6E, lane 2). Expression of the Y705F mutant corresponded with a loss of Y705
phosphorylation but had no overall impact on S727 phosphorylation (Fig 6E, compare lanes 1
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Fig 6. STAT3 is required for viral gene expression in undifferentiated keratinocytes. A) Left: Representative western blots of HPV18 containing
keratinocytes transfected with a panel of 4 STAT3 specific siRNA and a scrambled control and analysed by western blotting using a total STAT3 antibody
and antibodies detecting the E6 and E7 HPV18 early proteins. GAPDH served as loading control. Right: Quantification of the STAT3 protein band
intensities standardised to GAPDH levels. Data are expressed as fold reduced compared to scramble siRNA treated cells. Bars represent the
means ± standard deviation of at least three biological repeats. p<0.01 (Student’s t-test). B) Samples treated as in (A) and RNA extracted for qRT-PCR
determination of the stat3 and HPV early gene expression levels. Samples were normalized against U6 mRNA levels and data are presented relative to the
scrambled control. Bars represent means ± standard deviation of at least three biological repeats. P<0.05 (Student’s t-test). C) Representative western
blots from HPV18 containing keratinocytes treated with increasing doses of the STAT3 inhibitor cryptotanshinone and analysed with antibodies specific
for phosphorylated and total STAT3, and E6 and E7 HPV18 early proteins. GAPDH served as a loading control. Data are representative of at least three
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and 2). Likewise, expression of S727A ablated the observed S727 phosphorylation but did not
reduce Y705 phosphorylation (Fig 6E, compare lanes 3 and 4). Over-expression of the phos-
phorylation site mutants had negligible impact on STAT5 phosphorylation (S2C Fig). Notably,
expression of either of the phosphorylation site mutants led to a substantial reduction in
HPV18 E6 and E7 protein expression (Fig 6E). Taken together, these data demonstrate that
STAT3 phosphorylation at both Y705 and S727 is essential for HPV oncogene expression in
undifferentiated keratinocytes.
We hypothesized that STAT3 might control HPV early gene expression by binding directly
to the HPV genome. Indeed, recent chromatin immunoprecipitation sequencing (ChIP-Seq)
data observed STAT3 binding to the long control region (LCR) of integrated virus genomes in
the HPV18-positive HeLa cervical cancer cell line [58]. The LCR is bound by a number of host
transcription factors and is essential for driving early viral transcription [59]. We used ChIP
followed by qPCR to investigate whether STAT3 bound to the LCR of HPV18 episomes in pri-
mary keratinocytes [60]. In contrast to observations in the cancer cell line, we failed to detect
significant STAT3 enrichment at the LCR of HPV18 in undifferentiated cells (Fig 6F). Our
combined data demonstrates a requirement for STAT3 phosphorylation and activation in
HPV oncogene expression; likely independent of a direct interaction between STAT3 and the
viral LCR.
Suppression of STAT3 impairs cell cycle progression and results in loss of
HPV18 genome maintenance in undifferentiated keratinocytes
Considering that STAT3 is well known for its proliferative effects, we asked whether STAT3
contributes towards E6 and E7 gene expression by facilitating cell proliferation. We investi-
gated the effects of cryptotanshinone on the STAT3-dependent gene product and key cell cycle
regulator, cyclin D1. Western blot analyses were performed to determine the expression of
cyclin D1 in undifferentiated HPV-positive keratinocytes after 24 hours of cryptotanshinone
treatment. Fig 7A showed that cryptotanshinone decreased the expression of cyclin D1 in a
dose-dependent manner. Lower levels of cyclin D1 protein expression correlated with signifi-
cantly (p<0.01) lower levels of cyclin D1 mRNA in these cells as confirmed by qRT-PCR (Fig
7B). In keeping with inhibitor studies, depletion of total STAT3 protein by siRNA (Fig 7C) or
expression of phosphorylation site dominant negative forms of STAT3 (Fig 7D) also resulted
in reduced cyclin D1 expression in HPV positive keratinocytes. STAT3 also inhibits cell cycle
arrest and senescence through inhibition of the cyclin dependent kinase (CDK) inhibitor
p21WAF1/CIP1. Suppression of p21WAF1/CIP1 expression is facilitated indirectly by suppression
of the p53 tumour suppressor protein [61], or thought to occur directly by formation of a
STAT3-cyclin D1 transcriptional repressor complex bound to the p21WAF1/CIP1 promoter [62].
Loss of STAT3 expression and activity led to an up-regulation of p21WAF1/CIP1 expression at
biological repeats. D) RNA was extracted from HPV18 containing keratinocytes treated with 10 μM cryptotanshinone and qRT-PCR analysis performed
for levels of HPV E6 and E7 mRNA. Samples were normalized against the U6 mRNA levels and expressed relative to the DMSO control. Bars represent
means ± standard deviation of at least three biological repeats. P<0.05 (Student’s t-test). E) Representative western blots from HPV18 containing
keratinocytes transduced with a lentivirus encoding a dominant negative Y705F phospho-site mutant or transiently transfected with a dominant negative
STAT3 S727A mutant and analysed by blotting with antibodies specific for phosphorylated and total STAT3 and the E6 and E7 HPV18 early proteins. An
antibody detecting the FLAG epitope confirmed expression of the Y705F STAT3 mutant and GAPDH served as a loading control. Data shown are
representative of at least three biological repeats. F) Association of STAT3 with HPV18 genomes was assessed in HPV18 containing keratinocytes by
ChIP with control antibody (rabbit IgG) or STAT3-specific antibody. Co-precipitating DNA was analysed by qPCR. The x axis represents the position in
the HPV genome amplified and each data point represents the central point in each amplicon. Enrichment of STAT3 binding is expressed as fold over
IgG negative control calculated by the ΔΔCT method. The data represent the mean and standard deviation of three independent experiments. A graphical
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Fig 7. Suppression of STAT3 impairs cell cycle progression and HPV genome maintenance in undifferentiated keratinocytes. A) Representative western
blots from HPV18 containing keratinocytes treated with increasing doses of the STAT3 inhibitor cryptotanshinone and analysed with antibodies specific for
cyclin D1 and p21. GAPDH served as loading control. Data are representative of at least three biological independent repeats. B) RNA was extracted from
HPV18 containing keratinocytes incubated with 10 μM cryptotanshinone and analysed by qRT-PCR for levels of ccnd1 and p21 mRNA. Samples were
normalised against U6 mRNA levels and presented relative to the DMSO control. Bars represent means ± standard deviation of at least three biological
repeats. P<0.01 (Student’s t-test). C) Representative western blots of HPV18 containing keratinocytes transfected with a panel of 4 STAT3 specific siRNA
and a scrambled control and analysed by western blotting using antibodies specific for cyclin D1 and p21. GAPDH served as loading control. Data are
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both the protein and transcript level (Fig 7A–7D). Given that cell cycle progression depends
on the sequential expression of stage-specific cyclins and the activity of their corresponding
CDKs we examined the cell cycle profiles of HPV positive keratinocytes in which STAT3 activ-
ity was impaired. In the presence of cryptotanshinone, more keratinocytes were observed in S
phase (p<0.05) with a concomitant decrease (p<0.001) in the fraction of cells in G2/M (Fig
7E). Of note, cryptotanshinone treatment had no impact on the cell cycle profile of normal
human keratinocytes (Fig 7F). To rule out any non-specific effects of inhibitor treatment we
confirmed a similar cell cycle block in HPV18-containing keratinocytes when STAT3 was
depleted by siRNA (p<0.001) (Fig 7G). These observations are consistent with a delay in tran-
sit of cells from S to G2 phase upon inhibition of STAT3 in HPV18-containing cells, but not in
normal human keratinocytes.
The importance of STAT3 for maintaining efficient cell cycle progression prompted us to
assess whether STAT3 was necessary for stable HPV genome maintenance in undifferentiated
cells. HPV containing keratinocytes were grown in undifferentiated monolayer culture and
incubated with cryptotanshinone for 48 hours to impair STAT3 activity or transfected with a
pool of STAT3-specific siRNA to deplete total protein. Total DNA was isolated from these
cells and analysed by Southern blotting for levels of virus genomic DNA. There was a reduc-
tion in HPV episome levels when STAT3 activity was ablated by small molecule inhibitor
(62%) or total STAT3 protein removed by siRNA (30%) (Fig 7H). Together, these data demon-
strate a role for STAT3 in maintaining cell cycle progression and stable genome maintenance
in undifferentiated keratinocytes.
STAT3 is important for cell cycle progression and HPV18 genome
amplification in differentiated keratinocytes
Given that levels of STAT3 phosphorylation were maintained upon keratinocyte differentia-
tion, we wished to assess if STAT3 was also needed for the differentiation-dependent stages of
the HPV18 life cycle. HPV18-containing keratinocytes were co-cultured for 48 hours in media
containing high calcium to induce differentiation and cryptotanshinone to block STAT3 acti-
vation. Whilst levels of phosphorylated STAT3 and total E6 and E7 early proteins were main-
tained upon differentiation in control cells, they were suppressed by cryptotanshinone (Fig
8A; compare lanes 2 and 3). By maintaining high levels of cyclins, HPV-containing cells
remain active in the cell cycle upon differentiation to allow for virus genome amplification. In
accordance with this, upon differentiation high levels of cyclin D1 were maintained, and
expression of the CDK inhibitor p21WAF1/CIP1 was not elevated (Fig 8A; compare lanes 1 and
2). Blockade of STAT3 activation reduced cyclin D1 levels in differentiated cells (Fig 8A; com-
pare lanes 2 and 3), and consistent with the observed down-regulation of cell cycle pathways,
cryptotanshinone increased the expression of p21WAF1/CIP1 (Fig 8A; compare lanes 2 and 3).
The switch between keratinocyte proliferation and differentiation is tightly controlled and
STAT3 has been identified as a regulator of this process [25]. Therefore, we asked whether
STAT3 contributed to the suppression of keratinocyte differentiation observed during the
representative of at least three biological independent repeats. D) Representative western blots from HPV18 containing keratinocytes transduced with a
lentivirus encoding a dominant negative Y705F phospho-site mutant or transiently transfected with a dominant negative STAT3 S727A mutant and analysed
by blotting with antibodies specific for cyclin D1 and p21. GAPDH served as loading control. Data are representative of at least three biological independent
repeats. Representative flow cytometric analysis of the cell cycle in E) HPV18 containing keratinocytes or F) normal human keratinocytes treated with 10 μM
cryptotanshinone. G) As in E except cells treated with a pool of four STAT3 specific siRNAs. Data are expressed as percentage of cells at each stage of the cell
cycle. Bars represent means ± standard deviation of at least three biological repeats. P<0.05, P<0.001 (Student’s t-test) compared to DMSO or scrambled
control cells. H) Representative Southern blot analysis of undifferentiated HPV18 containing keratinocytes treated with 10 μM cryptotanshinone or a pool of
four STAT3 specific siRNAs.
https://doi.org/10.1371/journal.ppat.1006975.g007
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HPV life cycle. In untreated keratinocytes harbouring HPV18 genomes, levels of the differenti-
ation-specific proteins involucrin and filaggrin did not increase significantly upon incubation
in high calcium media (Fig 8A; compare lanes 1 and 2). In contrast, cells treated with crypto-
tanshinone displayed enhanced expression of these differentiation-dependent proteins (Fig
8A; compare lanes 2 and 3). These experiments indicate that STAT3 regulates the cell cycle
and differentiation marker expression in differentiating HPV-positive keratinocytes. To inves-
tigate if STAT3 was also important for differentiation-dependent HPV18 genome amplifica-
tion, HPV18 containing cells were treated with STAT3 inhibitors and differentiated by
suspension in methylcellulose prior to harvesting the DNA for Southern blotting. Western
blot analysis confirmed similar effects of STAT3 inhibition on HPV18 gene expression and
keratinocyte proliferation and differentiation marker expression in the methylcellulose differ-
entiated keratinocytes (Fig 8B). Moreover, treatment with cryptotanshinone significantly
reduced amplification of HPV18 genomes upon keratinocyte differentiation (Fig 8C and 8D).
These data indicate that STAT3 is required for differentiation-dependent stages of the HPV
life cycle.
Fig 8. STAT3 is important for cell cycle progression and HPV18 genome amplification in differentiated keratinocytes. Representative western blots of
phosphorylated and total STAT3, HPV18 E6 and E7, cyclin D1, p21, involucrin and filaggrin in A) calcium or B) methylcellulose-differentiated HPV18 containing
keratinocytes in the presence or absence of 10 μM cryptotanshione. Data shown represent at least three biological repeats. C) Southern blot analysis of HPV18
episomes in keratinocytes treated with 10 μM cryptotanshinone and differentiated in methylcellulose for 120 hours. DNA was linearized with EcoRI, producing a
single band running at approximately 8 kbp, demonstrating a differentiation-dependent increase in viral episome copy number in untreated control cells and a
reduction in episome copy number in cells treated with cryptotanshinone. Digestion with BglII shows a lack of detectable multimeric/integrated HPV genomes in all
experimental conditions. Data shown are representative of two donor cell lines. D) Signal intensity was quantified using ImageJ software. Bars represent
means ± standard deviation of two biological repeats from two donor cell lines.
https://doi.org/10.1371/journal.ppat.1006975.g008
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STAT3 is necessary for delayed differentiation and increased keratinocyte
proliferation in stratified epithelia
Our monolayer differentiation assays suggested that the ability of HPV to promote cell cycle re-
entry and delay differentiation was dependent on active STAT3. To address this in the context
of a fully stratified epithelium, NHK and HPV18-containing keratinocytes were transduced
with a lentivirus expressing the dominant negative phosphorylation site Y705F STAT3 mutant
or an empty vector control (pFugW). The Y705F mutant was utilized as it appeared marginally
more effective at impairing HPV gene expression compared to the S727A mutant (Fig 6D and
6E). Forty-eight hours after transduction cells were seeded onto collagen plugs and grown as
organotypic raft cultures, and sections stained with haematoxylin and eosin (Fig 9A). In com-
parison to NHK epithelium, the presence of HPV18 genomes was associated with a thickening
of the parabasal and spinous cell layers as previously shown [13]. Whilst the over-expression
of a dominant negative STAT3 protein had no impact on the morphology of NHK rafts, the
overall thickness of rafts produced from HPV18-containing cells expressing STAT3-Y705F
was consistently reduced, and their appearance more closely resembled the morphology of the
structures produced from the normal donor cells (higher magnification image in S5A Fig).
Amplification of the viral genome occurs in suprabasal cells that have entered a protracted
G2 phase of the cell cycle, and these cells can be identified by accumulation of cytoplasmic
cyclin B1 [63]. Thus, to assess cell cycle status of suprabasal cells, rafts were stained for cyclin
B1. In NHK, cyclin B1 was only observed in the basal layers of the raft and this was unaffected
by transduction with the Y705F STAT3 mutant (S5B Fig). In contrast, we observed a signifi-
cant (p<0.001) decrease in the population of cyclin B1 positive suprabasal cells following stain-
ing of the Y705F transduced HPV18 rafts, relative to empty vector transduced HPV18 rafts
(Fig 9B and 9E). These data illustrate the failure of cells lacking active STAT3 to maintain cell
cycle activity in the upper stratified layers.
Immunofluorescent staining of the differentiation marker involucrin was used to assess the
differentiation state of the rafts. As an intermediate stage differentiation marker, involucrin is
found in the suprabasal compartment of a normal epithelium (S5C Fig). Empty vector trans-
duced HPV18 rafts showed a delayed staining pattern, with expression restricted to the upper
suprabasal layers of the epithelium (Fig 9C). In contrast, abundant involucrin staining was
noted throughout the spinuous layers of the epithelium in rafts transduced with the dominant
negative Y705F phosphorylation mutant. Sections were also stained for the viral protein
E1^E4, a marker of productive infection [32,64]. E1^E4 staining was observed in the mid and
upper suprabasal layers of HPV18 control rafts, but was significantly (p<0.001) reduced in
rafts expressing STAT3 Y705F (Fig 9D and 9E; a wide field image available in S5D Fig). Taken
together, these data indicate that active STAT3 is dispensable for the formation of a stratified
epithelium in NHK, but is necessary for increased suprabasal cellular proliferation and cell
cycle progression in cells harbouring HPV18 genomes. STAT3 function also contributes to the
delay in differentiation and expression virus proteins observed in HPV-positive cells.
STAT3 expression and phosphorylation positively correlates with disease
state in cervical cancer samples
Although STAT3 phosphorylation was increased in primary keratinocytes containing HPV18,
we queried whether aberrant STAT3 phosphorylation correlated with cervical cancer initiation
and progression. Initially, we utilized the W12 in vitro model system [65]. The W12 system
was developed from a polyclonal culture of cervical squamous cells naturally infected with
HPV16, derived by explant from a low-grade squamous intraepithelial lesion (LSIL). At early
passages these cells recapitulate an LSIL in organotypic raft cultures. However, following long-
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Fig 9. STAT3 is necessary for delayed differentiation and increased keratinocyte proliferation in a stratified
epithelium. A) Representative organotypic raft cultures of NHK and HPV18-containing keratinocytes transduced
with empty lentivirus and lentivirus expressing a dominant negative phosphorylation null Y705F mutant STAT3 fixed
at day 14 and stained with haematoxylin and eosin (H&E) to assess morphology. Sections were also stained with
antibodies specific for B) cyclin B1 C) involucrin and D) E1^E4. Nuclei are visualised with DAPI (blue) and white
dotted lines indicate the basal cell layer. E) The number of cells positive for cyclin B1 and E1^E4 in the empty vector
and Y705F STAT3 transduced HPV18-containing keratinocyte sections was counted in 5 fields of vision from sections
of three independent raft cultures from two donor lines. Bars represent means ± standard deviation. P<0.001
(Student’s t-test) compared to empty vector control.
https://doi.org/10.1371/journal.ppat.1006975.g009
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term culture these cells mirror the events associated with cervical cancer progression, with
phenotypic progression to high-grade intraepithelial lesions (HSIL) and squamous cell carci-
noma. Organotypic raft cultures were generated from NHK cells and a W12 clone representing
a HSIL phenotype and stained for STAT3 S727 phosphorylation. In contrast to the NHK con-
trol, high levels of S727 phosphorylation was observed in the nuclei of cells throughout the
basal and suprabasal layers of the HSIL raft (Fig 10A). These data confirm that STAT3 S727
phosphorylation is greater in a high-grade lesion compared to NHK control cells. They also
confirm that increased STAT3 S727 phosphorylation is observed in the context of a high-risk
HPV16 infection.
Next, cervical liquid based cytology samples from a cohort of HPV16 positive patients rep-
resenting the progression of disease development (CIN1-CIN3) and HPV negative normal cer-
vical tissue controls were collected from the Scottish HPV archive and examined for the levels
of STAT3 protein and phosphorylated STAT3. Western blot analysis of the samples showed
that in normal cervical tissue STAT3 expression and phosphorylation was low (Fig 10B). How-
ever, STAT3 expression and its phosphorylation increased in the disease samples and this sig-
nificantly correlated with the degree of disease severity (Fig 10B–10E). Finally, we used
immunofluorescence to examine phosphorylated STAT3 S727 levels in a series of human cer-
vical sections classified as LSIL (CIN1), LSIL with foci of HSIL (CIN1/CIN2) and CIN3. An
analysis of the staining pattern showed a clear difference between the three groups (Fig 10F),
with greater STAT3 S727 phosphorylation in the high-grade neoplasia compared with lower
grade lesions. Together, these findings demonstrate that STAT3 phosphorylation is increased
in HPV positive keratinocytes including those of a natural HPV infection and correlate with
cervical disease progression.
Discussion
This study identifies the STAT3 transcription factor as a critical regulator of the HPV life
cycle. Using calcium and methylcellulose-mediated differentiation in monolayer, and organo-
typic raft culture models of primary human keratinocytes harbouring HPV18 episomes, we
discovered that STAT3 was necessary for HPV18 gene expression and viral DNA replication
in undifferentiated cells and in stratified epithelium. In undifferentiated cells, a loss of STAT3
transcription factor activity—brought about through the use of small molecule inhibitors or
expression of dominant negative STAT3 phosphorylation mutant proteins—led to a reduction
in HPV oncogene expression. This required the transcription factor function of STAT3, but it
did not entail direct binding of STAT3 to the viral LCR. Our findings are in contrast to ChIP-
Seq studies gathered from the HPV18-positive HeLa cervical cancer cells. This may in part be
due to differences in STAT3 expression levels between primary keratinocytes and cancer cell
lines. It is also possible that additional changes to the host cell signalling machinery or the inte-
gration of the viral genome, allow for STAT3 binding. The mechanism by which STAT3 acti-
vates HPV gene expression is therefore likely to be indirect. One possible mechanism would
be to generate a cellular milieu favourable for virus transcription. In this regard, STAT3 is a
driver of cell cycle progression and keratinocyte proliferation. Our results show that undiffer-
entiated HPV-containing keratinocytes express cyclin D1 and this is largely STAT3-dependent
as STAT3 inhibitor treatment, or depletion by siRNA resulted in a loss of proliferative marker
expression and an increase in expression of the cell cycle arrest protein p21WAF1/CIP1. Further-
more, these changes correlated with induction of S phase arrest. This likely results from the
reduced expression of cyclin D1, which in actively cycling cells must be increased in order for
cells to transition into G2. A similar S-phase arrest is observed in Epstein Barr virus infected
lymphoblastoid cell lines (LCLs), where STAT3 is required to relax the intra-S phase
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Fig 10. STAT3 expression and phosphorylation is increased in HPV-associated cervical disease. A) Representative immunofluorescence analysis of sections
from organotypic raft cultures of NHK and a W12 cell line presenting with HSIL morphology detecting pS727 STAT3 levels (green). Nuclei were visualized with
DAPI (blue) and the white dotted line indicates the basal layer. Images were acquired with identical exposure times. B) Representative western blots from
cytology samples of CIN lesions of increasing grade analysed with antibodies specific for phosphorylated (Y705 and S727) and total STAT3 levels. GAPDH
served as a loading control. C-E) Scatter dot plot of densitometry analysis of a panel of cytology samples. 20 samples from each clinical grade (neg, CIN I-III)
were analysed by western blot and densitometry analysis was performed using ImageJ. Phosphorylated STAT3 levels were first normalised against total STAT3
levels before normalising against protein levels using GAPDH as a loading control. F) Representative immunofluorescence analysis of tissue sections from
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checkpoint [66]. Intriguingly, STAT3 inhibition had no discernable impact on the cell cycle
profile of normal human keratinocytes, indicating that STAT3 is non-essential in HPV nega-
tive cells.
STAT3 regulates the stable maintenance of HPV episomes in undifferentiated cells and
inhibition of STAT3 transcription factor activity reduces stable episome copy numbers. This
can also be explained by the change in cellular proteins brought about by blockade of STAT3
transcriptional activity, which might deprive the virus of host factors essential for genome
maintenance. The loss of HPV early protein expression associated with inhibition of STAT3
activity is also likely to contribute to the deficit in virus transcription and genome mainte-
nance. Both E6 and E7 have been shown to be critical for cell cycle progression in keratino-
cytes and loss of either protein impairs genome maintenance [15]. In particular, the ability of
E6 to stimulate the degradation of the p53 tumour suppressor protein is important for
episomal maintenance in undifferentiated keratinocytes [13,67]. We observed an increase in
p53 expression in cells lacking E6 expression and also noted a significant up-regulation of the
p53 target gene product p21WAF1/CIP1. Whilst p21WAF1/CIP1 expression is negatively regulated
by STAT3, it is plausible that p53 contributes to the increases observed in cells lacking active
STAT3. Finally, there may be additional yet to be defined, viral or cellular proteins that are reg-
ulated by STAT3, which are important for episomal maintenance.
Since STAT3 is important for regulating stem cell like proliferative abilities along with con-
trolling differentiation [24,68], we investigated whether STAT3 played a role in these proper-
ties during the HPV life cycle. As expected, our results show that HPV18-containing
keratinocytes are differentiation resistant and retain their proliferative potential. This
enhanced capacity is largely dependent on STAT3 as inhibitors of transcription factor activity
or dominant negative STAT3 phosphorylation mutants reduced cyclin D1 expression in
monolayer culture. Consistent with this notion, loss of STAT3 activity imparted a reduction in
the proliferative capacity of a HPV-containing stratified epithelium resulting in increased
expression of keratinocyte differentiation markers. Rafts expressing the dominant negative
STAT3 protein retained the ability to stratify but were significantly altered in the expression of
cell cycle regulators and differentiation markers. In particular, suprabasal cells were no longer
active in the cell cycle as judged by the reduction in cyclin B1 staining. As HPV genome ampli-
fication is reliant on a prolonged G2 phase of the cell cycle, the loss of suprabasal cyclin B1 pro-
tein expression might account for the reduction in HPV genome amplification upon
differentiation in cells lacking active STAT3 [63,69]. Alternatively, whilst poorly characterised,
both E6 and STAT3 expression have been linked to the activation of the ATM-dependent
DNA damage response, a key player in HPV DNA replication [70,71]. It would be interesting
to determine whether E6-mediated activation of STAT3 might contribute to this key process.
Despite the loss of hyperplasia in the HPV18-containing rafts, the overall morphogenesis of
the epithelium appeared intact and reminiscent of a normal epithelium. This suggests that
whilst STAT3 phosphorylation was essential for increased proliferation, it was dispensable for
normal skin development. The minimal impact on raft morphology observed in normal kerati-
nocytes expressing the dominant negative STAT3 protein further illustrates that STAT3
appears not to be required for normal epithelial stratification. These results are in accordance
with studies using gene-targeted mice containing a keratinocyte specific STAT3 knockout.
These mice display no overt gross morphological differences in epithelial development but are
profoundly impaired in their capacity to undergo effective wound healing in response to injury
cervical lesions of increasing CIN grade. Sections were stained for pS727 STAT3 levels (green) and nuclei were visualized with DAPI (blue). Images were
acquired with identical exposure times. Scale bar, 20 μm.
https://doi.org/10.1371/journal.ppat.1006975.g010
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[27]. In contrast, mice engineered to express a constitutively active STAT3 in the proliferating
epithelial compartment exhibit hyperplasia and a perturbed differentiation programme [28].
They are also predisposed to develop skin malignancies. Our findings clearly suggest that
active STAT3 is necessary for suprabasal proliferation.
Our studies show that HPV infection leads to enhanced STAT3 Y705 and S727 phosphory-
lation that are maintained at high levels during keratinocyte differentiation without an alter-
ation to the total levels of STAT3. Interestingly, we demonstrated that expression of all three
HPV oncoproteins could induce STAT3 phosphorylation to a certain degree, but only E6 was
sufficient to induce the dual phosphorylation and activation of STAT3. This is consistent with
previous observations showing increased STAT3 Y705 phosphorylation in HPV-positive can-
cer cell lines, and leading to increased levels of STAT3-dependent gene products [43,72]. A
number of cellular pathways converge to phosphorylate and activate STAT3 [18,20]. Conven-
tional dogma for STAT3 activation implicates Y705 phosphorylation as necessary and suffi-
cient to activate STAT3 in response to a number of stimuli [18]. In addition, phosphorylation
of S727 within the transactivation domain of STAT3 has also been documented to activate
STAT3 signalling under some conditions. Using phosphorylation null dominant negative
STAT3 proteins our results clearly demonstrate that mono-phosphorylation of either site is
insufficient to activate the STAT3 dependent genes analysed in this study within keratinocytes
harbouring HPV and that dual phosphorylation is essential for the virus life cycle. Moreover,
our work does not support previous findings that S727 phosphorylation is detrimental to Y705
phosphorylation [73]. Rather, we suggest a model of interdependent phosphorylation between
Y705 and S727 sites, in which mutation of one site does not impede the phosphorylation of the
other. Our work also sheds light on the identity of the host kinases that phosphorylate these
sites in HPV containing primary keratinocytes. Using validated pharmacological inhibitors we
demonstrate that Y705 phosphorylation is critically dependent on JAK2 activity. Whilst JAK
kinases are the best characterised mediators of Y705 phosphorylation in other cellular systems,
to the best of our knowledge no study has shown that E6 up-regulates their activity. Since they
function downstream of growth factor and gp130 cytokine receptor pathways, it is possible
that E6 up-regulates an upstream component which subsequently activates JAK2 to phosphor-
ylate STAT3 Y705. In this regard, E6 activates the EGF receptor and increases IL-6 and oncos-
tatin-M expression, which mediate their effects via gp130 receptors [74–76]. On-going
experiments are testing whether these pathways contribute to STAT3 phosphorylation in pri-
mary keratinocytes. The mechanisms that mediate S727 phosphorylation are less clear due to a
wide field of potential candidate kinases. As a first step we focused on MAPK proteins, given
the presence of a strong consensus motif adjacent to S727. We found that similar to what has
been reported for p38 MAPK, the phosphorylation of all three canonical MAPK proteins
(ERK1/2, p38 and JNK1/2) is dysregulated in HPV containing cells [77]. Our studies suggest
that inhibition of all three MAPK members is required to fully impair STAT3 S727 phosphory-
lation. Given that E6 can activate all three kinases, our results suggest that functional redun-
dancy exists between the different MAPK members, providing an opportunity for S727
phosphorylation throughout differentiation. Whilst E6AP-mediated p53 degradation and
PDZ domain binding are well-characterised attributes of high-risk E6 proteins, neither of
these functions was required for the increase in STAT3 phosphorylation. Studies are now
uncovering a wealth of additional E6 binding partners and the functional consequences of
these interactions [78,79]. Use of further E6 mutants defective for binding to additional cellu-
lar targets will allow further investigation of the molecular basis for activation of these
pathways.
Although the crucial role of STAT3 in both tumour cells and the tumour microenviron-
ment is evident, gaps remain in our understanding of the regulation of STAT3 signalling in
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cancer. In particular, how S727 contributes to cancer development has not been fully eluci-
dated. Given the crucial role of phosphorylation of this site for HPV containing keratinocyte
proliferation, we further investigated STAT3 protein expression and phosphorylation levels in
HPV associated cancers. A clear trend was evident showing an abundance of STAT3 protein
and increased levels of STAT3 phosphorylation in high-grade HPV lesions compared to low-
grade lesions, or control cervical samples. Moreover, staining showed obvious STAT3 S727
nuclear localization in high-grade lesions, suggesting active STAT3. Whilst STAT3 inhibitors
are not yet clinically available, it might be possible to treat HPV-associated malignancies either
by targeting STAT3 directly or an upstream target such as JAK2. Overall, these studies demon-
strate that in addition to being activated in HPV-associated cancers, STAT3 is critically impor-
tant for the productive HPV life cycle and a possible target for therapeutic intervention.
Methods and materials
Ethics statement
Neonate foreskin tissues were obtained from local General Practice surgeries and foreskin ker-
atinocytes isolated in S. Roberts’ laboratory under ethical approval no. 06/Q1702/45.
Inhibitors
The STAT3 inhibitor S3I-201 was purchased from AdooQ BioSciences and used at a final con-
centration of 10 μM. This cell permeable compound binds to the STAT3 SH2 domain to pre-
vent phosphorylation and activation. Cryptotanshinone was purchased from LKT
Laboratories and used at a final concentration of 10 μM to inhibit STAT3 dimerisation and
activation. The STAT5 inhibitor Pimozide was purchased from Calbiochem and used at a final
concentration of 10 μM, as previously described [37]. UO126 is a selective MKK1/2 inhibitor,
and is used to inhibit activation of ERK1/2. It was added to cells at a final concentration of
20 μM and purchased from Calbiochem [80]. VX-702 was purchased from Tocris and used to
inhibit p38 kinase activity. It is highly specific and used at a final concentration in cells of
10 μM [53]. The JNK1/2 inhibitor JNK-IN-8 was purchased from Cambridge BioSciences and
used at a final concentration of 3 μM in cells [55]. SB-747651 was used to inhibit MSK1/2 and
used at a final concentration of 5 μM in cells [81]. The JAK1/2 inhibitor Ruxolitinib, and JAK2
inhibitor Fedratinib were kindly provided by Dr Edwin Chen, University of Leeds and used at
a final concentration of 10 μM [44]. All compounds were used at concentrations required to
minimise potential off-target activity.
Plasmids and siRNAs
Plasmids expressing HPV16 oncoproteins fused to an amino-terminal GFP protein were pre-
viously described [82,83]. GFP18 E5 was previously described [83]. E6 and E7 sequences were
amplified from the HPV18 genome and cloned into peGFP-C1 with SalI and XmaI and SalI
and BamHI restriction enzymes. Mutations were engineered into HPV18 E6 to disable interac-
tions with E6AP, p53 and PDZ domain containing proteins. A single point mutation was
introduced to create HPV18 E6 F4V and a C-terminal truncation lacking the final four amino
acids created HPV18 E6 ΔPDZ. These mutants were generated using Q5 DNA polymerase and
cloned into peGFP using SalI and XmaI. The L52A mutagenesis was performed by Genewiz
(New Jersey, USA) and cloned into peGFP using EcoRI and BamHI restriction sites. The plas-
mids driving Firefly luciferase from the β-casein promoter and a constitutive Renilla luciferase
reporter (pRLTK) were previously described [34]. pRc/CMV-STAT3 S727A (8708) [56],
pcFugW (14883), pcFugW-EF.STAT3DN.Ubc.GFP (24984) [57] and pGL3-PomC (17553)
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[35] were purchased from Addgene (Cambridge, MA, USA) and we thank the principle inves-
tigators Jim Darnell, David Baltimore, Linzhao Cheng and Domencino Accili for depositing
them.
Cell transfection
The transfection of primary human foreskin keratinocytes (NHK) isolated from neonate fore-
skin tissues (ethical approval no. 06/Q1702/45) was performed in S. Roberts’ laboratory as
described previously [13]. Briefly, plasmids containing the HPV18 genome were digested with
EcoRI to release the genome, which was then re-circularised with T4 DNA ligase. The genomes
were co-transfected with a plasmid encoding resistance to neomycin into low passage NHK in
serum free medium. One day later, the cells were harvested and seeded onto a layer of γ-irradi-
ated J2-3T3 fibroblasts and selected with G418 in complete E media containing foetal calf
serum (FCS, Lonza) and epidermal growth factor (EGF, BD BioSciences) for 8 days. Cell colo-
nies were pooled and expanded on γ-irradiated J2-3T3 fibroblasts. To account for donor-spe-
cific effects, NHK from two donors were used.
Organotypic raft cultures
Keratinocytes containing wild type HPV18 genomes or the mutant E6ΔPDZ genome were
grown in organotypic raft cultures by seeding the keratinocytes onto collagen beds containing
J2-3T3 fibroblasts [13]. Once confluent the collagen beds were transferred onto metal grids
and fed from below with FCS-containing E media without EGF. The cells were allowed to
stratify for 14 days before fixing with 4% formaldehyde. The rafts were paraffin-embedded and
4 μm tissue sections prepared (Propath UK, Ltd., Hereford, UK).
For analysis of Phospho-STAT3 (S727) (ab32143, abcam), Total STAT3 (C-20: sc-482,
Santa Cruz Biotechnology and 9132, CST), involucrin (SY5, Santa Cruz Biotechnology) and
HPV18 E1^E4 (mouse monoclonal antibody 1D11 [84]) expression, the formaldehyde-fixed
raft sections were treated with the sodium citrate method of antigen retrieval. Briefly, sections
were boiled in 10 mM sodium citrate with 0.05% Tween-20 for 10 minutes. Sections were
incubated with appropriate antibodies and immune complexes visualized by using Alexa 488
and 594 secondary antibodies (Invitrogen). The nuclei were counterstained with the DNA
stain 4’,6-diamidino-2-phenylindole (DAPI) and mounted in Prolong Gold (Invitrogen).
Southern blot analysis
Total genomic DNA was extracted from cell culture by phenol chloroform extraction and ana-
lysed on a 0.8% agarose gel and DNA transferred to GeneScreen nylon membrane. Complete
HPV18 genome was released from the pGEMII backbone vector by EcoRI digestion, purified
and labelled with [α-32P]-CTP. The membrane was incubated with this radiolabelled linear
probe at 42˚C overnight. Following washing the membrane was exposed to auto-radiograph
film [13].
Monolayer differentiation assays
Untransfected NHK and HPV18 containing keratinocytes were grown in complete E media
until 90% confluent. Media were changed to serum free keratinocyte media without supple-
ments (SFM medium, Invitrogen) containing 1.8 mM calcium chloride. Cells were maintained
in this media for between 48–72 hours before lysis and analysis. Alternatively, keratinocytes
were resuspended in E-Media containing 1.5% methylcellulose and cultured for 120 hrs prior
to harvesting.
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Transfections and mammalian cell lysis
Transient transfections were performed with a DNA to Lipofectamine 2000 (ThermoFischer)
ratio of 1:4. 48 h post transfection, cells were lysed in Leeds lysis buffer for western blot [85].
In vitro kinase assay
Human recombinant STAT3 (Sigma SRP2062) was incubated with 10 mU active JNK1, ERK2
or p38α in 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 10 mM magnesium acetate, 0.1 mM
Na3VO4, 0.1% (v/v) 2-mercaptoethanol and 0.1 mM [γ
32P] ATP for 30 minutes at 30˚C. The
reaction was terminated by the addition of 5x SDS sample buffer (0.24 M Tris-HCl pH6.8, 8%
(w/v) SDS, 40% (v/v) glycerol, 5% (v/v) 2-mercaptoethanol). Incorporation of phosphate was
determined following SDS-PAGE and autoradiography or immunoblotting with pS727
STAT3 antibody. For autoradiography, the gel was stained with Instant Blue (Expedeon) for
1h at room temperature, destained in water and exposed to film at -80˚C. Protein bands were
excised from the gel and γ32P measured by Cerenkov counting in a liquid scintillation counter.
The pSTAT3 western blot and the Coomassie stained gel were imaged using a LiCor Odyssey
and quantified using Image Studio software.
Western blotting
Total protein was resolved by SDS-PAGE (10–15% Tris-Glycine), transferred onto Hybond
nitrocellulose membrane (Amersham biosciences) and probed with antibodies specific for
Phospho-STAT3 (S727) (ab32143, abcam), Phospho-STAT3 (Y705) (9131, Cell Signalling
Technology (CST)), Total STAT3 (C-20: sc-482, Santa Cruz Biotechnology), Phospho-STAT5
(Y694) (9314, CST), Phospho-JAK2 (Y1007/1008) (3776, CST), Total JAK2 (3230, CST), invo-
lucrin (SY5, Santa Cruz Biotechnology), HPV18 E6 (G-7, Santa Cruz Biotechnology), HPV18
E7 (8E2, Abcam (ab100953), HPV 16/18 E6 (C1P5, Santa Cruz Biotechnology), HPV 16 E7
(ED17, Santa Cruz Biotechnology), Phospho-ERK1/2 (Thr202/Tyr204) (43705, CST), Phos-
pho-JNK (Thr183/Tyr185) 4668, CST), Phospho-p38 (Thr180/Tyr182) (9211, CST), Bcl xL
(H-62, Santa Cruz Biotechnology), Cyclin D1 (A-12, Santa Cruz Biotechnology) p53 (FL-393,
Santa Cruz Biotechnology), p21 (2947, CST), FLAG (F3165, Sigma), GFP (B-2: sc-9996, Santa
Cruz Biotechnology) and GAPDH (G-9, Santa Cruz Biotechnology). Western blots were visu-
alized with species-specific HRP conjugated secondary antibodies (Sigma) and ECL (Thermo/
Pierce).
Flow cytometry
Keratinocytes were incubated for 48 hours with STAT3 inhibitors or transfected with STAT3
siRNA, harvested and fixed in 70% ethanol overnight. The ethanol was removed and cells
washed with PBS containing 0.5% BSA. Cells were stained with PBS containing 0.5% BSA,
50 μg/ml propidium iodide (Sigma) and 5 μg/ml RNase (Sigma) and incubated in this solution
for 30 minutes at room temperature. Samples were processed on an LSRFortessa cell analyzer
(BD) and the PI histograms analyzed on modifit software.
Lentivirus transduction
Lentivirus plasmids were transfected into HEK 293TT cells with envelope and GAG/polymer-
ase plasmids (kindly provided by Professor Greg Towers, University College London) using
PEI transfection reagent. After 48 hours the medium was removed from the HEK 293TT cells
and added to keratinocytes for 3 hours. After this time, the complete E medium was replaced
and the cells incubated for 48 hours.
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Quantitative real-time PCR
Total RNA was extracted from NHK using the E.Z.N.A. Total RNA Kit I (Omega Bio- Tek)
according to the manufacture’s protocol. One μg of total RNA was DNase treated following
the RQ1 RNase-Free DNase protocol (Promega) and then reverse transcribed with a mixture
of random primers and oligo(dT) primers using the qScript cDNA SuperMix (Quanta Biosci-
ences) according to instructions. qRT- PCR was performed using the QuantiFast SYBR Green
PCR kit (Qiagen). The PCR reaction was conducted on a Corbett Rotor-Gene 6000 (Qiagen)
as follows: initial activation step for 10 min at 95˚C and a three-step cycle of denaturation (10
sec at 95˚C), annealing (15 sec at 60˚C) and extension (20 sec at 72˚C) which was repeated 40
times and concluded by melting curve analysis. The data obtained was analysed according to
the ΔΔCt method using the Rotor-Gene 6000 software [86]. Specific primers were used for
each gene analysed and are shown in S1 Table. U6 served as normaliser gene.
Chromatin immunoprecipitation
ChIP experiments were carried out in primary foreskin keratinocytes containing episomal
HPV18 genomes as previously described [60]. ChIP efficiency throughout the HPV18 genome
was assessed by quantitative PCR (qPCR) using SensiMix SYBR master mix (Bioline). Primer
sequences are available on request. STAT3 association with the cyclin D1 promoter was
assessed in each individual ChIP experiment using previously described primer sequences
[87].
Statistical analysis
Where indicated, data was analyzed using a two-tailed, unpaired Student’s t-test.
Supporting information
S1 Fig. Depletion of E6 in HPV containing keratinocytes reduces STAT3 phosphorylation.
A) Representative western blots of HPV18-containing keratinocytes transfected with a pool of
two HPV18 E6 specific siRNA and analysed with antibodies specific for phosphorylated and
total STAT3, HPV18 E6 and E7 and p53. GAPDH expression was used as a loading control. B)
Representative western blots of HPV18-containing keratinocytes transfected with a HPV18 E7
specific siRNA and analysed with antibodies specific for phosphorylated and total STAT3,
HPV18 E6 and E7. GAPDH expression was used as a loading control. C) Representative west-
ern blots of HPV18-containing keratinocytes and HPV18 E5KO-containing keratinocytes sub-
jected to high calcium differentiation and analysed for phosphorylated and total STAT3.
GAPDH serves as a loading control. D) Representative sections of organotypic raft cultures
from HPV18 wild type and HPV18 E5KO-containing keratinocytes stained with antibodies
specific for pS727 STAT3 and counterstained with DAPI to highlight the nuclei (blue in the
merged panels). Images were acquired using identical exposure times. Scale bar, 20 μm. White
dotted lines indicate the basal cell layer.
(TIFF)
S2 Fig. Modulation of STAT3 in primary keratinocytes does not affect STAT5 phosphory-
lation. A) Representative western blot of HPV18-containing keratinocytes differentiated in
high calcium media for 48 h and untreated or treated with 10 μM cryptotanshinone analysed
with an antibody specific for phosphorylated STAT5. B) Representative western blot of
HPV18-containing keratinocytes treated with 4 individual STAT3 specific siRNAs or a scram-
ble control and analysed with an antibody specific for phosphorylated STAT5. C) Representa-
tive western blot of HPV18-containing keratinocytes transduced with a lentivirus encoding a
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STAT3 Y705F mutant or transiently transfected with a STAT3 S727A expression plasmid and
analysed with an antibody specific for phosphorylated STAT5. GAPDH expression was used
as a loading control in all western blots. All experiments were performed independently at
least three times.
(TIFF)
S3 Fig. Phosphorylation of STAT3 S727 by recombinant MAPK proteins. Recombinant
STAT3 was incubated in in vitro kinase reactions with recombinant MSK1, JNK1, ERK2 and
p38α as described in materials and methods. Proteins were analysed by SDS PAGE and protein
bands excised from the gel and γ32P measured by Cerenkov counting in a liquid scintillation
counter. Data are represented relative to a no kinase control.
(TIFF)
S4 Fig. Cryptotanshinone does not cause cytotoxicity in HPV18-containing primary kera-
tinocytes. A) HPV18-containing primary keratinocytes treated with increasing doses of cryp-
totanshinone and analyzed for cell viability by MTT assay. Bars represent the
means ± standard deviation of at least three independent experiments.
(TIFF)
S5 Fig. Additional images of organotypic raft cultures. A) Representative images of H&E
stained organotypic raft cultures of NHK and HPV18-containing keratinocytes transduced
with empty lentivirus or lentivirus expressing Y705F STAT3 and imaged at 40x magnification.
Organotypic raft cultures of NHKs were stained with antibodies specific for B) cyclin B1 and
C) involucrin. Nuclei are visualised with DAPI (blue) and white dotted lines indicate the basal
cell layer. D) Representative sections from HPV18-containing raft cultures transduced with
empty lentivirus or lentivirus expressing Y705F STAT3 and stained with an antibody specific
for E1^E4. DAPI stained nuclei (Blue) and dotted white lines indicate basal layer. Widefield
image 40x magnification.
(TIFF)
S1 Table. A list of primer sequences used in the quantitative RT-PCR experiments. The
table includes gene name and sequences of forward and reverse primers.
(TIFF)
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